FDA Diabetes Panel Fattens Lineup With April 1 Review Of Onglyza

Bristol-Myers stays mum on cardiovascular events in trials; agency’s demands are soon to become clearer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet